Cover Image

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin

Roberto J Carvalho-Filho1, Olav Dalgard21Division of Gastroenterology, Hepatitis Section, Federal University of São Paulo, São Paulo, Brazil; 2Department of Medicine, Rikshospitalet, Oslo, NorwayAbstract: Chronic infection with hepatitis C virus (HCV) is a major public health p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Roberto J Carvalho-Filho (Author), Olav Dalgard (Author)
Format:	Book
Published:	Dove Medical Press, 2010-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population
by: Mario Espinosa, et al.
Published: (2015)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
by: R. Rodríguez-Lojo, et al.
Published: (2010)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
by: Yasser K. Rashed, et al.
Published: (2020)

Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients
by: Ravinder Dhillon, et al.
Published: (2008)

Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection
by: Mona H Ismail
Published: (2013)

Adverse Skin Reactions due to Ribavirin in Hepatitis C Combination Therapy with Pegylated Interferon-α2a
by: Masahisa Shindo, et al.
Published: (2013)

Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy
by: Hu CC, et al.
Published: (2018)

Seminal parameters before and during combined antiviral (pegylated interferon α-2a and ribavirin) treatment in chronic hepatitis C virus patients in upper Egypt
by: Hussein M Ghanem, et al.
Published: (2014)

PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) TO PEGYLATED INTERFERON ALPHA (PEG-IFN α) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1.
by: Krasimir Antonov, et al.
Published: (2011)

Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
by: Ming-Han Hsieh, et al.
Published: (2022)

Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C
by: Dorta Guridi Zaily, MD, PhD, MS, PM, et al.
Published: (2017)

Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy
by: Bassem Refaat, et al.
Published: (2015)

Psoriasis induced by Interferon alfa-2a and ribavirin in a patient followed for hepatitis C
by: N. Amraoui, et al.
Published: (2015)

Erythema annulare centrifugum-like eruption associated with pegylated interferon treatment for hepatitis C
by: Mark Naccarato, et al.
Published: (2013)

Pegylated Interferon Associated Thyroidal Dysfunction Among Hepatitis C Patients
by: Nida Sajid, et al.
Published: (2024)

Polymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1 Patients Treated by Pegylated Interferon and Ribavirin
by: Fahimeh Safarnezhad Tameshkel, et al.
Published: (2016)

Borderline tuberculoid leprosy and type 1 leprosy reaction in a hepatitis C patient during treatment with interferon and ribavirin
by: Mônica Santos, et al.
Published: (2013)

Treatment of acute hepatitis C virus infection with interferon-α 2b and ribavirin: Case report and review of the literature
by: Sunbul Mustafa, et al.
Published: (2002)

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin
by: Junior André da Rosa, et al.
Published: (2012)

Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings
by: Alima ALMADIYEVA, et al.
Published: (2018)

The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study
by: Juferdy Kurniawan, et al.
Published: (2019)

Erosive oral lichen planus after pegylated-interferon therapy for chronic hepatitis B
by: Ellie Choi, MMed, MRCP, et al.
Published: (2018)

Toll-like receptors 7 and 8 mRNA in monocytes of Egyptian children with chronic hepatitis C infection genotype 4 as predictor to "response" interferon and ribavirin treatment
by: Mohammed A. Khedr, et al.
Published: (2016)

Impact of "Sambhav" Program (Financial Assistance and Counselor Services) on Hepatitis C Pegylated Interferon Alpha Treatment Initiation in India
by: Ajit Sood, et al.
Published: (2018)

Systematic review and meta-analysis: de novo combination of nucleos(t)ide analogs and pegylated interferon alpha versus pegylated interferon alpha monotherapy for the functional cure of chronic hepatitis B
by: Na Wei, et al.
Published: (2024)

Increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy
by: Shin-Yu Lu, et al.
Published: (2009)

Effectiveness of Ombitasvir with Paritaprevir/Ritonavir plus Ribavirin on the Treatment of Naïve Patients with Chronic Hepatitis C Virus Genotype 4
by: Mohammed Abdel-GAbbar, et al.
Published: (2022)

Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C
by: Kuroda Masahiko, et al.
Published: (2010)

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
by: Yi He, et al.
Published: (2022)

Frequency Of Depressive And Anxiety Symptoms Among Patients On Interferon And Pegylated Interferon
by: Muhammad Waseem Shaikh, et al.
Published: (2024)

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection
by: Hussien Ahmed, et al.
Published: (2017)

Hyercalcemia induced by interferon therapy in chronic hepatitis C
by: Waleed I Albaker
Published: (2012)

Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment
by: Carine Raquel Blatt, et al.
Published: (2014)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
by: Ide K, et al.
Published: (2016)

Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin
by: Mohamed DA Abd Alla, et al.
Published: (2018)

A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
by: Hsuan-Yu Hung, et al.
Published: (2021)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
by: Cocco E, et al.
Published: (2015)

A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B
by: Li J, et al.
Published: (2021)

El interferón en el tratamiento de la hepatitis C crónica Inmunobiología básica e inmunopatología del hígado Interferon treatment of chronic hepatitis C: Basic immunobiology and immunopathology of the liver
by: J.S. Mazana
Published: (2013)

Restoration of natural killer cell activity in chronic hepatitis C-infected Egyptian patients treated by sofosbuvir/daclatasvir with or without ribavirin
by: Hamdy M Moustafa, et al.
Published: (2021)